Type 2 Diabetes Mellitus and Heart Failure: A Position Statement from the Heart Failure Association of the European Society of CardiologyPetar Seferović, John J.V. McMurray, Mark C. Petrie et al.|European Journal of Heart Failure|2018Cited by 716
Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and Without Diabetes (LIVE)—a Multicentre, Double-Blind, Randomised, Placebo-Controlled TrialAnders Jorsal, Lise Tarnow, Caroline Kistorp et al.|European Journal of Heart Failure|2016Cited by 561
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure PatientsRoni Nielsen, Henrik Wiggers, Jens Nørkær Sørensen et al.|Circulation|2019Cited by 513
Ketone Body Infusion With 3‐Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography StudyLars Christian Gormsen, Niels Møller, Mads Svart et al.|Journal of the American Heart Association|2017Cited by 235
Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failureMads Halbirk, Henrik Wiggers, Helene Nørrelund et al.|American Journal of Physiology-Heart and Circulatory Physiology|2010Cited by 165